Cannformatics


Tools For Individualized Medical Cannabis

A bioinformatics platform that evaluates the physiological condition of the individual to indicate which cannabis strain and dosage will be most effective for their specific condition, while minimizing undesirable side effects.

We are building a database to better understand the relationship between an individual’s biology and the many complexities of the cannabis plant. In the future, we will be collecting anonymous saliva samples, with perks for early participants. If you’re interested in being a part of Cannformatics, please provide us with the information you are comfortable sharing.

To sign up for the private beta just answer these 3 questions (less than a minute).

OR

For more information contact us here.

Itzhak Kurek


- CEO and Co-Founder

Background:

Dr. Kurek is a senior biotech leader with experience in managing, consulting and research roles in the Ag-Biotech, Human and Nutritional Supplements, Renewable Energy and Biobased Products businesses. Dr. Kurek joined Cannformatics from Solix Algredients, a B2B supplier of algae-based natural ingredients where he served as R&D consultant at the Vice-President level. Previously, Dr. Kurek worked at Kiverdi inc., a company making high-value oils and chemicals from waste carbon sources, as the Senior Director of R&D. Dr. Kurek held research scientist positions at Pioneer Hi-Bred (DuPont), Verdia Inc. and Maxygen Inc. Dr. Kurek has published 20 peer reviewed scientific papers and 10 granted US and international patents cited over 1,800 times.

Dr. Kurek received his Ph.D. in Plant Sciences from Tel Aviv University and completed his postdoctoral research at the University of California, Davis. Dr. Kurek has also conducted research at the Technical University of Munich, John Innes Center Norwich, C.N.R.S Bordeaux and the Lawrence Berkeley National Laboratories.

Robert McKee


- CTO and Co-Founder

Background:

Mr. McKee is a patent lawyer with expertise in genetics, machine learning/artificial intelligence, data privacy law and technology commercialization. Mr. McKee joined Cannformatics from his law practice where he writes patents and ensures compliance with data privacy laws, and develops IP protection strategies for very early stage companies to ensure value creation. Previously, Mr. McKee worked at Kiverdi Inc., a company making high-value oils and chemicals from waste carbon sources, as IP and Business Development Associate. Mr. McKee held a microbiologist position at the Texas Department of State Health Services.

Mr. McKee received his Master of Science in Technology Commercialization from the Red McCombs School of Business at the University of Texas, Austin. He holds a JD from the University of Houston, Texas and a BS in Microbiology from The University of Texas, Austin. Mr. McKee has also completed the UDACITY Machine Learning Engineer Nanodegree.

Mike Siani-Rose


- VP of Computational Chemistry

Background:

Mr. Siani-rose has 20+ years of experience in regenerative medicine, biotechnology and bioinformatics. At Cannformatics, he provides project leadership for strategic corporate partnerships, leadership on computational biology and computational chemistry. He has been a project management consultant to Big Pharma/Biotech, directing projects that reach broadly across manufacturing organizations. Previously, as President and Founder of Theregen he raised $10M and led the company from preclinical through IND and two Phase I clinical trials for the implantable Anginera epicardial patch. He has extensive expertise in computational chemistry, drug discovery and bioinformatics from positions at Chiron Corporation (now Novartis), Kosan Biosciences and Affymetrix.

Mike has 45+ publications, and ten issued patents in drug discovery, laboratory automation, bioinformatics, and regenerative medicine. He received his BS in Chemical Engineering from the University of Rochester, did graduate work in Computer Science at UCSD, and attended the BioExecutive Institute in the Haas School of Business at UC Berkeley.